Zimmer Biomet Holdings, Inc. to Issue Quarterly Dividend of $0.24 (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced a quarterly dividend on Friday, May 22nd. Stockholders of record on Thursday, June 25th will be paid a dividend of 0.24 per share by the medical equipment provider on Friday, July 31st. This represents a c) annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th.

Zimmer Biomet has a dividend payout ratio of 11.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Zimmer Biomet to earn $8.91 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Trading Down 0.8%

Shares of NYSE:ZBH opened at $87.29 on Tuesday. The firm has a market cap of $16.89 billion, a price-to-earnings ratio of 22.67, a PEG ratio of 2.59 and a beta of 0.47. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29. The company’s fifty day simple moving average is $87.13 and its 200 day simple moving average is $90.05. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts forecast that Zimmer Biomet will post 8.49 EPS for the current fiscal year.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Zimmer Biomet by 6.1% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 399,826 shares of the medical equipment provider’s stock valued at $39,383,000 after buying an additional 22,992 shares during the last quarter. Inceptionr LLC acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $1,217,000. Wilsey Asset Management Inc. acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $32,439,000. Dimensional Fund Advisors LP raised its stake in Zimmer Biomet by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider’s stock valued at $223,503,000 after acquiring an additional 39,146 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after acquiring an additional 13,883 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.